NCT06074588 trial: what clinicians have said so far
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06074588 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT06074588 (sacituzumab tirumotecan in previously treated advanced nonsquamous NSCLC with genomic alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06074588 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan; Docetaxel; Pemetrexed
- Arms
- Sacituzumab tirumotecan · Experimental
- Chemotherapy · Active comparator
- Enrollment
- 556 (estimated)
- Primary outcomes
- Overall Survival (OS) of Participants with NSCLC with Epidermal Growth Factor Receptor (EGFR) Mutations
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Nov 12, 2023
- Primary completion
- May 10, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06074588 · updated Aug 14, 2026